<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372381</url>
  </required_header>
  <id_info>
    <org_study_id>55</org_study_id>
    <nct_id>NCT04372381</nct_id>
  </id_info>
  <brief_title>Supra-Annular vs. Annular ValvEs for Small Annuli</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Supra-Annular vs. Annular ValvEs for Small Annuli (&lt;= 23mm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marvin Eng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, prospective randomized comparison of Supra-annular valves (Medtronic Evolut Pro)
      vs. annular valves (Edwards Sapien Ultra) for small annuli (≤23 mm)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient prothesis mis-match (PPM) remains a clinical dilemma in transcatheter aortic valve
      replacement (TAVR) and has been linked to higher rates of morbidity and mortality.
      Supra-annular self-expanding valves have been linked to lower gradients and lower rates of
      patient prosthesis mismatch versus annular valves but they have not been directly compared.
      Patients with small annuli are particularly vulnerable to PPM, therefore, the aprior
      hypothesis is that implantation of supra-annular valves for small annuli may show differences
      in PPM rates and outcomes when compared to annular valves.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 4, 2020</start_date>
  <completion_date type="Anticipated">May 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-Label, Prospective randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of patient prosthesis mismatch and &gt;= moderate paravalvular regurgitation</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VARC-2 30-day early safety and efficacy</measure>
    <time_frame>30 days</time_frame>
    <description>All cause mortality stroke life-threatening bleeding acute kidney injury-stage 2 or 3 coronary artery obstruction major vascular complication valve-related dysfunction requiring repeat procedure NYHA class III or IV Requiring hospitalization for valve-related symptoms or worsening congestive heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical indication for permanent pacemaker insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic Valve Dysfunction</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Mean aortic valve gradient &gt;= 20 mmHg
&gt;= Moderate transvalvular aortic regurgitation Abnormal leaflet thickening Decreased leaflet mobility Leaflet thrombosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Implantation, Heart Valve Prosthesis</condition>
  <arm_group>
    <arm_group_label>Supra-Annular transcatheter heart valve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic Evolut Pro Valve implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Annular transcatheter heart valve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edwards Sapien 3 Ultra implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro</intervention_name>
    <description>Treatment of aortic valve stenosis using transcatheter aortic valve replacement</description>
    <arm_group_label>Annular transcatheter heart valve</arm_group_label>
    <arm_group_label>Supra-Annular transcatheter heart valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic subjects with severe native aortic valve stenosis

          -  aortic valve annulus mean diameter ≤23 mm

          -  Patient meet commercial indication for transcatheter aortic valve replacement (TAVR)

          -  Institutional heart team determines that TAVR is appropriate

          -  Patient's anatomy is appropriate for either Medtronic Evolute or Edwards Sapien 3
             Ultra

        Exclusion Criteria:

          -  Subject unable or unwilling to provide informed consent

          -  Intended concurrent structural heart procedure (e.g. transcatheter mitral valve repair
             or replacement, left atrial appendage closure)

          -  Renal function precluding the administration of iodinated contrast (eGFR &lt;
             30ml/min/1.73m2). An exception to this exclusion criterion is made if the subject is
             established on renal replacement therapy and is therefore able to receive intravenous
             iodinated contrast media

          -  Pregnancy or intent on becoming pregnant prior to completion of all proctocol
             follow-up procedures

          -  Patients at high risk for coronary obstruction

          -  Patients with low-flow low gradient aortic valve stenosis

          -  patients at high risk for annular rupture with implantation of a balloon expandable
             valve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin Eng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kacorri, Ardit, MD</last_name>
    <phone>3139167452</phone>
    <phone_ext>3139167452</phone_ext>
    <email>akacorr1@hfhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Eng, MD</last_name>
      <phone>313-207-5515</phone>
      <phone_ext>3132075515</phone_ext>
      <email>meng1@hfhs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Marvin Eng</investigator_full_name>
    <investigator_title>Structural Heart Disease Fellowship Director</investigator_title>
  </responsible_party>
  <keyword>Implantation, Heart Valve Prosthesis</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>transcatheter aortic valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

